BeOne (ONC) Secured a Pharmaceutical-Tariff Exemption After More than $1B of U.S. Manufacturing Investment. Are the Pricing Concessions Worth It?
BeOne Medicines AG (NASDAQ:ONC) entered a voluntary agreement with the U.S.
Beone Medicines Ltd. (ONC)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Baker Bros. Advisors Julian Baker And Felix Baker | 8,801,567 | $2,508,182,548 | +1% | 12.57% |
| 2. | Citadel Investment Group Ken Griffin | 1,425,517 | $406,229,580 | +39% | 0.05% |
| 3. | Millennium Management Israel Englander | 543,323 | $154,830,755 | +166% | 0.06% |
| 4. | Siren L.L.C. Raymond Debbane | 465,000 | $132,511,050 | 2.68% | |
| 5. | GLG Partners Noam Gottesman | 307,463 | $87,617,731 | +28% | 0.14% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $302.06 | 165,529 | $49,999,938.03 | 18,943,802 | 2021-09-10 | Filing | |
| $108.00 | 5,231,900 | $565,045,200.00 | 5,250,491 | 2018-08-02 | Filing | |
| $108.00 | 582,200 | $62,877,600.00 | 600,791 | 2018-08-02 | Filing | |
| $101.00 | 1,645,148 | $166,159,948.00 | 5,121,404 | 2018-01-18 | Filing | |
| $101.00 | 335,050 | $33,840,050.00 | 708,025 | 2018-01-18 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $355.86 | 132 | $46,973.52 | 0 | 2026-09-01 | Filing | |
| $380.00 | 280 | $106,400.00 | 0 | 2026-08-25 | Filing | |
| $360.00 | 2,666 | $959,760.00 | 0 | 2026-08-11 | Filing | |
| $359.12 | 14,102 | $5,064,252.42 | 0 | 2026-08-12 | Filing | |
| $358.41 | 20,899 | $7,490,448.21 | 14,102 | 2026-08-12 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 5,007,931 | $1,427,110,097 | 0.84% | |
| 2. | 4,210,221 | $1,201,254,811 | 0.25% | |
| 3. | 2,478,527 | $706,305,845 | 0.03% | |
| 4. | 2,249,582 | $641,063,383 | 0.08% | |
| 5. | 845,729 | $241,007,393 | 0.65% |
News See All
FDA Approval Marks A Turning Point For BeOne Medicines (ONC)
On August 25, BeOne Medicines (NASDAQ:ONC) said the FDA approved TEVIMBRA in combination with ZIIHERA and chemotherapy as a first-line treatment for HER2-positive gastroesophageal adenocarcinoma, a hard...
Is BeOne Medicines AG (ONC) Deal With Revolution Medicines (RVMD) a Win-Win for Both Companies?
Two oncology powerhouses, BeOne Medicines AG (NASDAQ:ONC) and Revolution Medicines, Inc. (NASDAQ:RVMD), announced a major multi-part clinical collaboration and regional licensing deal.
Wall Street's 76 Biggest Earnings Winners
Latest data from financial data firm FactSet said an earnings per share growth of 15 percent or more is already considered an unusually strong result rather than a normal earnings outcome.
Is BeOne Medicines AG (ONC) Stock Positioned for Growth After Encouraging ASCO Cancer Data?
We recently compiled a list of the 10 Most Promising Cancer Stocks According to Wall Street Analysts. BeOne Medicines AG (NASDAQ:ONC) is one of the most promising stocks on our list.
10 Most Promising Cancer Stocks According to Wall Street Analysts
In this article, we will be taking a look at the 10 Most Promising Cancer Stocks According to Wall Street Analysts.
10 Most Promising Long-Term Stocks to Buy According to Analysts
In this article, we will discuss the 10 Most Promising Long-Term Stocks to Buy According to Analysts.
10 Most Promising Healthcare Stocks According to Wall Street Analysts
In this article, we will look at the 10 Most Promising Healthcare Stocks According to Wall Street Analysts.
15 High-Growth Large-Cap Stocks to Invest In Now
In this article, we will discuss the 15 High-Growth Large-Cap Stocks to Invest In Now.
10 Best European Growth Stocks to Buy
In this article, we will look at the 10 Best European Growth Stocks to Buy. European growth stocks are getting another look as investors search for earnings growth outside the usual U.S.